DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD

Information source: San Francisco Veterans Administration Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Stress Disorders, Post-Traumatic

Intervention: Doxazosin XL (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: San Francisco Veterans Administration Medical Center

Official(s) and/or principal investigator(s):
Anne Richards, MD, MPH, Principal Investigator, Affiliation: San Francisco Veterans Affairs Medical Center

Overall contact:
Christen Waldon, MSW, Phone: 415-221-4810, Ext: 3809, Email: christen.waldon@va.gov

Summary

This study will assess the effects of the medication doxazosin on sleep in men and women with PTSD. Sleep will be measured objectively at home using a portable sleep recorder and wrist actigraphy.

Clinical Details

Official title: A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Change in mean total sleep time and wake-time after sleep onset as measured by polysomnography and actigraphy

Change in REM sleep time and REM period duration as measured by polysomnography

Secondary outcome: Change in mean scores on the CAPS, CAPS sleep and distressing dreams items, PCL, BDI, ISI, PSQI, PSQI-A and QOLI

Detailed description: This pilot study will assess the effects of doxazosin on objective measures of sleep in PTSD subjects using home ambulatory polysomnography. Twenty (20) men and women with chronic PTSD will be enrolled at the San Francisco Veterans Affairs Medical Center. After initial screening, subjects will complete 1 week of baseline assessments including 2 nights of home ambulatory polysomnography. They will then participate in a 2-week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment ending with 2 nights of home polysomnography. Subjective and rater-based assessments will be conducted at baseline and at set intervals during and at the end of treatment. Wrist actigraphy measurements will also be made at baseline and at end of treatment as an economical, fairly valid and unobtrusive measure of sleep duration. We hypothesize that doxazosin will be associated with an increase in total sleep time (TST) and a decrease in wake time after sleep onset (WASO). We hypothesize that doxazosin will also be associated with clinical gains with respect to nightmares, subjective sleep quality, non-sleep PTSD symptoms, depression symptoms, and quality of life.

Eligibility

Minimum age: 18 Years. Maximum age: 69 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Age 18-69 2. Current full or partial syndromal PTSD of at least 3 months duration as indexed by the CAPS (Clinician-administered PTSD scale) score >30 3. CAPS recurrent distressing dreams item of >/= 5 Exclusion Criteria: 1. alcohol and or drug abuse/dependence in the last 3 months 2. lifetime history of any psychiatric disorder with psychotic features, bipolar disorder, obsessive-compulsive disorder 3. exposure to trauma within the last 3 months 4. prominent suicidal or homicidal ideation 5. sleep apnea diagnosis or positive screen for sleep apnea by Type III device. 6. neurologic disorder or systemic illness affecting CNS function 7. history of brain trauma or head injury with loss of consciousness greater than 10 minutes 8. chronic or unstable medical illness including unstable angina, myocardial infarction within the past 6 months, congestive heart failure, preexisting hypotension or orthostatic hypotension, chronic renal or hepatic failure, and pancreatitis 9. pregnancy, breastfeeding and/or refusal to use effective birth control 10. previous serious adverse reaction to an alpha-1-antagonist (such as priapism, hepatitis, angioedema, or intraoperative floppy iris syndrome) 11. current use of trazodone, hypnotics/benzodiazepines, mirtazapine, atypical antipsychotics, beta-adrenergic blockers, alpha-2-agonists, and current prazosin or other alpha-1-antagonists 12. previous non-response to prazosin for treatment of PTSD related sleep disturbance Participants taking SSRIs, bupropion, venlafaxine and duloxetine may be included if they have been on a stable dose for 2 months. Participants may be included if they have been stable in psychotherapy treatment for 2 months and/or if they begin no new psychotherapy while in the trial.

Locations and Contacts

Christen Waldon, MSW, Phone: 415-221-4810, Ext: 3809, Email: christen.waldon@va.gov

San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, United States; Recruiting
Christen Waldon, MSW, Phone: 415-221-4810, Ext: 3809, Email: christen.waldon@va.gov
Anne Richards, MD, MPH, Principal Investigator
Additional Information

Stress and Health Research Program - REST Study

Related publications:

De Jong J, Wauben P, Huijbrechts I, Oolders H, Haffmans J. Doxazosin treatment for posttraumatic stress disorder. J Clin Psychopharmacol. 2010 Feb;30(1):84-5. doi: 10.1097/JCP.0b013e3181c827ae.

Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008 Mar 15;63(6):629-32. Epub 2007 Sep 14.

Starting date: October 2013
Last updated: December 19, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017